Gilead Sciences, Inc. (NASDAQ:GILD)

CAPS Rating: 4 out of 5

A biopharmaceutical company that discovers, develops and commercializes innovative therapeutics in areas of unmet medical need.

Recs

2
Player Avatar CarolinaMatt (50.39) Submitted: 1/3/2011 6:57:07 PM : Outperform Start Price: $18.43 GILD Score: +417.97

Yes I get it. This company is no longer the high-flying early-stage pharma star with a everything under patent and profits growing as fast as it can ramp distribution.

But this is no old super-slow moving huge pharma company (i.e. Pfizer) either. Pricing is at a 2011 PE of about 9X which suggests maturity and minimal EPS growth. But this company is still projected to grow EPS at 15ish% over the next 3-5 years. Even if they fall short and come in at more like 10-11% EPS gains it is a bargain in the drug space.

Featured Broker Partners


Advertisement